首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1524253

可流動止血劑市場 - 依材料（牛、豬）、應用（一般外科、心血管、骨科、婦科、神經外科、重建外科）、最終用途（醫院和診所、ASC）、全球預測（2024 - 2032）

Flowable Hemostats Market - By Material (Bovine, Porcine), Application (General Surgery, Cardiovascular, Orthopedic, Gynecological, Neurosurgery, Reconstructive Surgery), End-use (Hospitals & Clinics, ASC's), Global Forecast (2024 - 2032)

出版日期: 2024年04月26日 | 出版商:

Global Market Insights Inc. | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

隨著全球醫療保健支出的增加，2024 年至 2032 年全球可流動止血劑市場的複合年成長率將超過 5.7%。隨著各國向醫療保健分配更多資源，將有更大的能力投資於改善手術結果的創新醫療解決方案。根據美國醫學會報告，2022年美國醫療保健支出成長4.1%，總計4.5兆美元，人均13,493美元。這一熱潮伴隨著醫療產品和服務的使用反彈，導致支出大幅增加。

這種趨勢在已開發經濟體中很明顯，人口老化和慢性病的增加需要複雜的治療方案。增加的資金支持在各種醫療環境中研究、開發和部署穩態藥物，提高其可近性和有效性。最終，更高的醫療支出為可流動止血劑等醫療技術的發展創造了有利的環境。

整個可流動止血劑市場根據材料、應用、最終用戶和地區進行分類。

由於豬的生物相容性和手術過程中控制出血的功效，豬隻在預測期內將錄得顯著的複合年成長率。豬源止血劑源自天然來源，使其適用於不同的患者群。它們能夠模仿人體的凝血機制，有效減少手術併發症並促進更快的癒合。此外，加工技術的進步確保了豬源止血劑的安全性和純度，進一步提高了其在臨床環境中的接受度。這一趨勢凸顯了醫療保健提供者和患者對手術體內平衡的自然、可靠解決方案的日益偏好。

由於可流動止血器在複雜手術過程中管理出血併發症方面發揮關鍵作用，到 2032 年，心血管手術領域將搶佔前景廣闊的可流動止血器市場佔有率。心血管手術通常涉及脆弱的組織，需要精確的穩態控制，以最大限度地降低風險並確保成功的結果。可流動止血器為外科醫生提供了一種多功能解決方案，可以輕鬆應用於各種手術場景，包括微創手術。它們能夠快速有效地止血，從而減少手術時間並支持患者康復。這種不斷成長的需求凸顯了可靠的穩態解決方案對於提高心血管護理中的手術精度和病人安全的重要性。

由於醫療保健基礎設施的發展、外科手術的增加和醫療保健標準的提高，到 2032 年，亞太地區可流動止血劑市場規模將經歷相當大的複合年成長率。該地區國家正在經歷快速的城市化和經濟成長，導致醫療保健支出增加和獲得先進醫療的機會增加。此外，人口老化和慢性病的流行需要手術中有效的穩態解決方案。醫療技術和支持性監管框架的創新進一步推動了可流動止血劑的採用，顯示亞太地區市場強勁的成長軌跡。

產業生態系統分析
產業影響力
- 成長動力
  - 全球外科手術數量不斷增加
  - 事故和創傷案件的發生率不斷增加
  - 體內平衡產品不斷進步的技術
- 產業陷阱與挑戰
  - 產品成本高
  - 替代方案的可用性
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產地分類，2021 - 2032 年

主要趨勢
牛科
豬

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
一般外科
心血管外科
骨科手術
婦科手術
神經外科
重建手術
其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院和診所
門診手術中心
其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

3D Matrix Medical Technology
Aegis Lifesciences Private Limited
Baxter International Inc.
CR Bard Inc. (Becton, Dickinson, and Company)
Ethicon, Inc. (Johnson & Johnson)
Ferrosan Medical Devices A/S
Integra LifeSciences Corporation
Medcura Inc.
Pfizer, Inc.
Teleflex Incorporated

簡介目錄

Product Code: 9238

Global Flow-able Hemostats Market will exhibit over 5.7% CAGR from 2024 to 2032, ushered by amplifying healthcare expenditure globally. As countries allocate more resources to healthcare, there is greater capacity to invest in innovative medical solutions that improve surgical outcomes. As per the American Medical Association report, health spending in the U.S. increased by 4.1% in 2022, totaling USD 4.5 trillion USD 13,493 per capital. This upsurge was accompanied by a rebound in the utilization of medical goods and services, contributing to significant expenditure growth.

This trend is evident in developed economies where aging populations and rising chronic diseases necessitate sophisticated treatment options. The increased funding supports research, development, and deployment of homeostatic agents in various medical settings, enhancing their accessibility and effectiveness. Ultimately, higher healthcare spending fosters a conducive environment for the growth of medical technologies such as flow-able hemostats.

The overall flow-able hemostats market is classified based on material, application, end-user, and region.

The porcine segment will record a noticeable CAGR during the forecast period, owing to their bio-compatibility and efficacy in controlling bleeding during surgical procedures. Porcine-derived hemostats are derived from natural sources, making them suitable for use in diverse patient populations. Their ability to mimic the body's clotting mechanisms effectively reduces surgical complications and promotes faster healing. Moreover, advancements in processing techniques ensure the safety and purity of porcine-derived hemostats, further boosting their acceptance in clinical settings. This trend underscores a growing preference for natural, reliable solutions in surgical homeostasis among healthcare providers and patients alike.

The cardiovascular surgery segment will grab a promising flow-able hemostats market share by 2032 due to the critical role of flow-able hemostats in managing bleeding complications during intricate procedures. Cardiovascular surgeries often involve delicate tissues and require precise homeostatic control to minimize risks and ensure successful outcomes. Flow-able hemostats provide surgeons with a versatile solution that can be applied easily in various surgical scenarios, including minimally invasive procedures. Their ability to quickly and effectively stop bleeding reduces operating times and supports patient recovery. This heightened demand underscores the importance of reliable homeostatic solutions in enhancing surgical precision and patient safety within cardiovascular care.

Asia Pacific flow-able hemostats market size will experience a considerable CAGR through 2032 because of spurring healthcare infrastructure development, rising surgical procedures, and improving healthcare standards. Countries in the region are witnessing rapid urbanization and economic growth, leading to higher healthcare expenditures and greater accessibility to advanced medical treatments. Moreover, the aging population and prevalence of chronic diseases necessitate effective homeostatic solutions in surgeries. Innovations in medical technology and supportive regulatory frameworks further propel the adoption of flow-able hemostats, indicating a robust market growth trajectory in the Asia Pacific.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing number of surgical procedures globally
  - 3.2.1.2 Increasing incidence of accidents and trauma cases
  - 3.2.1.3 Rising technological advancements in homeostasis products
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of products
  - 3.2.2.2 Availability of alternatives
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Origin, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Bovine
5.3 Porcine

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 General surgery
6.3 Cardiovascular surgery
6.4 Orthopedic surgery
6.5 Gynecological surgery
6.6 Neurosurgery
6.7 Reconstructive surgery
6.8 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals & clinics
7.3 Ambulatory surgical centers
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa